Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

A Wild CAR-T Race In China: The Hype, Reality And What Works

Executive Summary

As China overtakes the US as the largest developer of cell therapies including CAR-Ts, multiple issues ranging from clinical data to manufacturing are surfacing, potentially derailing a promising field. Executives from leading players Fosun-Kite, Juno-Wuxi and local heavyweight Legend shared insights on what works and what's needed to get things rights at a recent meeting in Suzhou.

You may also be interested in...



China's Draft Cell Therapy Guidelines Draws Concern From Industry

New draft guidelines could potentially create parallel clinical pathways for cell and gene therapies in China, and industry executives are worried about different standards for such emerging treatments in a country with the highest number of ongoing cell therapy trials in the world.

China CAR-T Front-Runner Allegations Reveal Soft Underbelly Of Development Race

A report from a short-seller group accuses Chinese firm Nanjing Legend of intentionally omitting clinical data for its CAR-T candidate, an allegation the company has refuted while global partner J&J says it remains "optimistic" about the product and conducted "careful" reviews of the data.

Gene Therapy INDs In China: Five Things To Consider

China is overtaking the US as the largest cell development market, with over 2,300 registered clinical trials. 

Topics

Related Companies

UsernamePublicRestriction

Register

SC124091

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel